Success Story: Advancing Precision Medicine Through Single-Cell Multi-Omics Research: NIW Approval Secured for a Biomedical Sciences Researcher from France
On September 22nd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Bioinformatics Analyst in the field of Biomedical Sciences (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: Senior Bioinformatics Analyst
Country of Origin: France
State of Residence at the Time of Filing: New York
Approval Notice Date: September 22nd, 2026
Processing Time: 1 year, 10 months, 7 days (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a biomedical sciences researcher whose work advances precision medicine through single-cell multi-omics and computational analysis. The client’s proposed endeavor focuses on mapping relationships between genetic variation and cellular characteristics to better understand disease mechanisms and support the development of more precise diagnostic tools and targeted therapies. At the time of filing, the client was employed as a Senior Bioinformatics Analyst at a U.S. medical research institution, where he analyzed genomic data and applied computational methods to investigate disease development.
Research with National Importance
The client’s research addresses important healthcare challenges by using single-cell multi-omics technologies to improve understanding of how genetic changes influence disease. His work supports advances in precision medicine by helping researchers identify disease-associated mutations and cellular pathways that may inform more accurate diagnosis and targeted treatment strategies. These contributions are particularly relevant to cancer research and other complex diseases and align with U.S. priorities in biotechnology, bioinformatics, and advanced biomedical research.
Academic Contributions and Recognition
At the time of filing, the client had authored 4 peer-reviewed journal articles, 1 conference abstract, and 2 preprints. His published work had received 82 citations, and he had completed at least 1 peer review for a scientific journal. His research appeared in highly regarded publication venues, while independent researchers relied on his findings in subsequent studies involving disease biology, cancer, cellular behavior, and genomic analysis.
Several of the client’s publications also demonstrated particularly strong citation impact, with 2 papers ranking among the top 0.1% and 2 among the top 10% most-cited articles in Molecular Biology & Genetics for their respective years of publication. Together with the documented use of his work by other researchers and expert support submitted with the petition, this record demonstrated the significance and broader influence of his research.
Recognition from Experts
Experts also highlighted the broader significance of the client’s research in advancing single-cell analysis and precision medicine.
One expert noted:
“...[client]’s research is important to fostering new single-cell computational platforms for unveiling somatic mutations, which in turn impacts healthcare expenditure, continued hospitalization rates, and resource distribution on a broader scale.”
This endorsement further supports the significance of the client’s work in developing computational approaches that improve understanding of disease mechanisms and contribute to more precise healthcare strategies.
NIW Approval and Outlook
The I-140 NIW petition was filed on November 15th, 2024, later upgraded to Premium Processing, and approved on September 22nd, 2026. The approval recognized the national importance of the client’s work in developing advanced computational approaches that improve disease characterization and support precision medicine.
This outcome supports the client’s continued efforts to advance biomedical research, genomic analysis, and precision medicine in the United States. We congratulate him on this approval and wish him continued success in advancing biomedical sciences research.